Brief: Pulmatrix To Regain Full Rights To PUR1800 And Narrow Spectrum Kinase Inhibitor Portfolio

Pulmatrix

12/04/2021 14:19

April 12 (Reuters) - Pulmatrix Inc  PULM.O :
    * PULMATRIX TO REGAIN FULL RIGHTS TO PUR1800 AND NARROW
SPECTRUM
KINASE INHIBITOR PORTFOLIO
    * PULMATRIX INC - TERMINATION OF LICENSE, DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT WITH LUNG CANCER INITIATIVE AT
JOHNSON & JOHNSON WILL RETURN PORTFOLIO TO PULMATRIX
    * PULMATRIX INC - TO CONTINUE DEVELOPMENT OF PUR1800 FOR
TREATMENT
OF ACUTE EXACERBATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    * PULMATRIX INC - LONG-TERM TOXICOLOGY DATA IN Q3 2021 HAS
POTENTIAL TO BROADEN DEVELOPMENT TO ADDITIONAL INDICATIONS
REQUIRING CHRONIC DOSING
    * PULMATRIX INC - PLANS TO INITIATE A PUR1800 PHASE 2B
PROOF-OF-CONCEPT EFFICACY STUDY FOR TREATMENT OF AECOP IN 2021

Source text for Eikon:  ID:nPnbpdRga 
Further company coverage:  PULM.O 

 ((Reuters.Briefs@thomsonreuters.com;))